Search clinical trials for: bendamustine and rituximab

Total 270249 results

Medical University of Vienna

Not yet recruiting

Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma

Mantle-cell Lymphoma
National Cancer Institute (NCI)

Withdrawn

Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Splenic Marginal Zone Lymphoma

United States
Georg Hess, MD
Wyeth is now a wholly owned subsidiary of Pfizer; Mundipharma Pte Ltd.

Completed

Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma (BERT)

Follicular Lymphoma | Mantle Cell Lymphoma

Germany
Samsung Medical Center

Unknown

Bendamustine Plus Rituximab for Mantle Cell Lymphoma: a Multicenter Retrospective Analysis(BR-MCL)

Mantle Cell Lymphoma

Korea, Republic of
International Extranodal Lymphoma Study Group (IELSG)

Completed

Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma

Marginal Zone B-cell Lymphoma

Italy, France
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

Efficacy and Safety of Bendamustine Plus Rituximab in Chronic Lympocytic Leukemia (LLC1315)

Chronic Lymphocytic Leukemia

Italy
The Lymphoma Academic Research Organisation

Terminated

BRIEF Bendamustine and Rituximab In Elderly Follicular (BRIEF)

Follicular Lymphoma

France, Belgium
Grupo Español de Linfomas y Transplante Autólogo...

Completed

Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma

MALT LYMPHOMA

Spain
Cephalon

Completed

SDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL)

Non-Hodgkin's Lymphoma

United States, Australia, Canada
National Research Center for Hematology, Russia

Unknown

Bendamustine in Combination With Rituximab as a First-line Therapy Followed by Maintenance Therapy With Rituximab in Patients With Follicular Lymphoma (BRiF)

Follicular Lymphoma

Russian Federation
Gruppo Italiano Studio Linfomi

Completed

Bendamustine and Rituximab As Salvage Therapy In Patients With Chronic Lymphoproliferative Disorders

Relapsed or Refractory Chronic Lymphoproliferative Disorders

Italy
Grupo Oncológico para el Tratamiento y el Estudio...

Unknown

Trial of Rituximab, Bendamustine (RB) for Patients With Follicular Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First Line

Follicular Non-Hodgking´s Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First Line.

Spain
Fondazione Italiana Linfomi ONLUS

Unknown

Rituximab Plus Bendamustine as Front Line Treatment in Frail Elderly (>70 Years) Patients With DLBCL: a Phase II Multicenter Study of the FIL

Diffuse Large B-cell Lymphoma

Italy
University of Göttingen
Roche Pharma AG; Mundipharma Research GmbH & Co KG

Completed

Rituximab and Bendamustine in Very Elderly Patients or Elderly Medically Non Fit Patients With Aggressive B-cell Lymphoma (B-R-ENDA)

Aggressive Lymphoma

Germany
Seoul National University Hospital
Chonbuk National University Hospital; Seoul National University Bundang Hospital and other collaborators

Completed

Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL)

Marginal Zone B-cell Lymphoma

Korea, Republic of
Southwest Oncology Group
National Cancer Institute (NCI)

Withdrawn

S0902 Bendamustine and Rituximab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Not Responded to Previous Treatment

Leukemia
Pharmatech
Cephalon

Completed

Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (904)

Diffuse Large B-Cell Lymphoma

United States
Celgene
The Lymphoma Academic Research Organisation

Active, not recruiting

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma (RELEVANCE)

Follicular Lymphoma

United States, Japan
Astellas Pharma Europe B.V.

Completed

Ribomustin in the First Line Therapy of Chronic Lymphocytic Leukemia (NORMA)

Chronic Lymphocytic Leukemia

Russian Federation
Astellas Pharma Europe B.V.

Completed

Ribomustin in the Second Line Therapy of Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma

Lymphoma, Non-Hodgkin

Russian Federation
Czech CLL Study Group

Completed

Observational Study in CLL Patients Receiving BR

Chronic Lymphocytic Leukemia

Czechia
Helse Fonna

Completed

Bendamustine and Rituximab Combination Therapy for Cold Agglutinin Disease (CAD5)

Autoimmune Hemolytic Anemia | Cold Agglutinin Disease

Finland, Denmark, Norway
Asan Medical Center
Cheolwon Suh

Recruiting

Bendamustine Plus Subcutaneous Rituximab in Patients With Diffuse Large B-cell Lymphoma (PTLD)

Diffuse Large B Cell Lymphoma

Korea, Republic of
Genentech, Inc.
AbbVie (prior sponsor, Abbott)

Withdrawn

A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed Diffuse Large B-Cell Lymphoma (NAVIGATE)

Diffuse Large B-Cell Lymphoma

United States
The Lymphoma Academic Research Organisation
Celgene Corporation

Active, not recruiting

A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma (RELEVANCE)

Follicular Lymphoma

Spain, Canada, France, Australia, Italy, Belgium, Germany, Portugal
University Hospital Tuebingen
Arbeitsgemeinschaft fur Internistische Onkologie; German Sarcoma Group

Completed

Bendamustin Hydrochloride in Patients With Soft Tissue Sarcoma (STS)

Sarcoma, Soft Tissue

Germany
Fondazione Italiana Linfomi ONLUS

Completed

Fase II Study With BRB for Non-Hodgkin Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia's (FIL_BRB)

Waldenstrom's Macroglobulinemia

Italy
Hoffmann-La Roche

Completed

A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe)

Lymphocytic Leukemia, Chronic

Finland, France, Spain, Portugal, Turkey, United Kingdom, Sweden, Tunisia
University of Rochester
Millennium Pharmaceuticals, Inc.; Cephalon

Completed

Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's Lymphoma (BVR)

Non-Hodgkin's Lymphoma

United States
Memorial Sloan Kettering Cancer Center

Completed

The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma

Lymphoma | Mantle Cell Lymphoma

United States
Incyte Corporation

Withdrawn

A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma (CITADEL-310)

Mantle Cell Lymphoma
Ruijin Hospital

Recruiting

A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma

Lymphoma, Mantle-Cell

China
Czech Lymphoma Study Group

Not yet recruiting

Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL (CLSGMCLPOLA)

Lymphoma, Mantle-Cell

Czechia
Charite University, Berlin, Germany
ribosepharm GmbH

Unknown

Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small Cell Lung Cancer (SCLC)

Recurrent Small Cell Lung Cancer

Germany
University of Wisconsin, Madison
Genentech, Inc.; Celgene Corporation

Withdrawn

Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL)
Institute of Hematology & Blood Diseases Hospital

Recruiting

Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WM (ZBR)

Waldenstrom Macroglobulinemia

China
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Terminated

CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
Yale University

Withdrawn

A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)

Hematopoietic/Lymphoid Cancer | Infectious Mononucleosis | PTLD | Lymphoid Tumor | Plasmacytic Hyperplasia PTLD | Florid Follicular Hyperplasia PTLD | Polymorphic PTLD | Monomorphic PTLD | Classical Hodgkin Lymphoma Type PTLD

United States
MorphoSys AG
ICON Clinical Research

Active, not recruiting

A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) (B-MIND)

Diffuse Large B-cell Lymphoma

United States, Hungary, Italy, Poland, Spain, Czechia, Germany, Australia, Austria, Canada, Croatia, Finland, France, Israel, Korea, Republic of, New Zealand, Portugal, Romania, Serbia, Singapore, Taiwan, Turkey, United Kingdom
University of Giessen

Completed

Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab

Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma

Germany
Kami Maddocks, MD
Pharmacyclics LLC.

Active, not recruiting

Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent... and other conditions

United States
UNC Lineberger Comprehensive Cancer Center
Cephalon

Completed

Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma

Lymphoma | Diffuse Large B-Cell Lymphoma | Lymphoma, Diffuse Large-Cell | Diffuse Large-Cell Lymphoma

United States
Cephalon

Completed

Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States, Canada
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Completed

Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma

Lymphoma

United States
AbbVie (prior sponsor, Abbott)
Genentech, Inc.

Completed

Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
University of California, Davis
Novartis

Completed

Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer

Multiple Myeloma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Adult Hodgkin Lymphoma | Refractory Chronic Lymphocytic Leukemia

United States
BeiGene

Active, not recruiting

Study Comparing Zanubrutinib + Rituximab Versus Bendamustine + Rituximab in Participants With Untreated Mantle Cell Lymphoma

Mantle Cell Lymphoma; Non-Hodgkin Lymphoma

Japan
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Bendamustine and Idarubicin in Treating Older Patients With Previously Untreated AML or MDS

Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) | Untreated Adult Acute Myeloid... and other conditions

United States
University of Magdeburg

Unknown

Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL

Lymphoma, High-Grade

Germany
Fondazione Italiana Linfomi ONLUS

Completed

Phase II Study of Age-Adjusted Rituximab, Bendamustine, Cytarabine as Induction Therapy in Older Patients With MCL (FIL-RBAC500)

Mantle Cell Lymphoma

Italy

Search clinical trials for: bendamustine and rituximab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Argentina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations